Evotec has partnered Bristol-Myers Squibb to launch another Bridge programme, this time focusing on the universities of Birmingham, Dundee, Edinburgh and Nottingham.
The universities of Birmingham, Dundee, Edinburgh and Nottingham have joined forces with drug discovery and development company Evotec and pharmaceutical firm Bristol-Myers Squibb to launch BeLab1407.
Equipped with $20m, BeLab1407 is the latest addition to Evotec’s international network of early-stage academic collaborations under the Bridge umbrella, and will focus on drug discovery.
Bridge was launched in 2016 through Lab282 at University of Oxford, with $16m of capital. The institution subsequently added Lab10x in 2019 to focus on digital therapeutics and…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
